The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

Sotyktu is not approved to treat rheumatoid arthritis. Adverse Reactions. The safety of Sotytku was assessed in 2 placebo- and active-controlled studies, PSO-1 and PSO-2, ...

The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis ...

Johnson & Johnson JNJ announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. "Today ...

Sotyktu (deucravacitinib) is a brand-name drug that’s prescribed for moderate to severe plaque psoriasis in certain adults. Sotyktu comes as an oral tablet that’s typically taken once per day.

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Bristol Myers Squibb today announced new three-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. These ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

Sotyktu can provide appropriate patients with the chance of clearer skin. In two studies of people with moderate to severe plaque psoriasis including 1,684 adults, ...